| EPB178 | Drug-drug interactions between antiretrovirals and remdesivir | E-poster | Drug interactions |
| EPB177 | Emtricitabine triphosphate in dried blood spots predicts current HIV viremia in people living with HIV and ongoing substance use disorders | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB176 | Pharmacokinetics (PK) and tolerability of cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) intramuscular (IM) injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB175 | Pharmacokinetic modeling and simulation of intramuscular and subcutaneous ibalizumab delivery | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB174 | Impact of intrinsic and extrinsic factors on the pharmacokinetics of long-acting lenacapavir for treatment of HIV | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB173 | Characterization of the absorption, metabolism, and excretion of islatravir, an HIV nucleoside reverse transcriptase translocation inhibitor, in humans | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB172 | Targeted delivery of dolutegravir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB171 | Efficacy of Tenofovir alafenamide versus tenofovir disoproxil fumarate among HIV positive Zambian adults switched from NNRTI to dolutegravir-containing ART: results from the VISEND clinical trial | E-poster | Regimen simplification and switch studies |
| EPB170 | Changes innonalcoholicfatty liverdiseasespectrum and metabolic markers in people with HIV after switching to a raltegravir-based regimen | E-poster | Regimen simplification and switch studies |
| EPB169 | Efficacy and safety of switching to Dolutegravir/Lamivudine by baseline regimen in virologically suppressed adults: 48-week pooled analysis | E-poster | Regimen simplification and switch studies |